Elevated peripheral blood glutamate levels in major depressive disorder

Masatoshi Inoshita,1 Hidehiro Umehara,1 Shin-ya Watanabe,1 Masahito Nakataki,1 Makoto Kinoshita,1 Yukiko Tomioka,1 Atsushi Tajima,2 Shusuke Numata,1 Tetsuro Ohmori1 1Department of Psychiatry, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan; 2Department of Bioinformati...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Inoshita M, Umehara H, Watanabe S, Nakataki M, Kinoshita M, Tomioka Y, Tajima A, Numata S, Ohmori T
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	glutamate major depressive disorder blood association study meta-analysis Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/54d0d76e83924955bf880a6f6e951cdc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:54d0d76e83924955bf880a6f6e951cdc
record_format	dspace
spelling	oai:doaj.org-article:54d0d76e83924955bf880a6f6e951cdc2021-12-02T05:55:41ZElevated peripheral blood glutamate levels in major depressive disorder1178-2021https://doaj.org/article/54d0d76e83924955bf880a6f6e951cdc2018-04-01T00:00:00Zhttps://www.dovepress.com/elevated-peripheral-blood-glutamate-levels-in-major-depressive-disorde-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Masatoshi Inoshita,1 Hidehiro Umehara,1 Shin-ya Watanabe,1 Masahito Nakataki,1 Makoto Kinoshita,1 Yukiko Tomioka,1 Atsushi Tajima,2 Shusuke Numata,1 Tetsuro Ohmori1 1Department of Psychiatry, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan; 2Department of Bioinformatics and Genomics, Graduate School of Advanced Preventive Medical Sciences, Kanazawa University, Ishikawa, Japan Purpose: There is growing evidence that glutamatergic signaling may be involved in major depressive disorder (MDD). In regard to peripheral blood glutamate changes in MDD, inconsistent findings have been reported. The purpose of the present study was to evaluate whether blood glutamate levels differed between MDD patients and control participants. Materials and methods: We conducted a systematic review and meta-analysis of 12 association studies between blood glutamate levels and MDD in a total of 529 MDD patients and 590 controls. Subsequently, we conducted subgroup analyses and a meta-regression analysis to examine the sources of potential heterogeneity. Results: A random effects model showed that blood glutamate levels were significantly higher in MDD patients than in controls (standardized mean difference=0.54, 95% CI=0.27–0.82, p=8.5×10-5) with high heterogeneity (I2=75.0%, p<0.05). Subgroup analyses showed elevated glutamate levels in MDD patients compared with controls in plasma, but not serum studies, and in studies using high-performance liquid chromatography but not with mass spectrometry for glutamate assay. A meta-regression analysis showed no effects of age, gender, medication use, sample size, and published year on blood glutamate levels. Conclusion: Our findings suggest that altered glutamate levels may be implicated in MDD, which provides further evidence of glutamatergic dysfunction in MDD. Keywords: glutamate, major depressive disorder, blood, association study, meta-analysisInoshita MUmehara HWatanabe SNakataki MKinoshita MTomioka YTajima ANumata SOhmori TDove Medical Pressarticleglutamatemajor depressive disorderbloodassociation studymeta-analysisNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 14, Pp 945-953 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	glutamate major depressive disorder blood association study meta-analysis Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	glutamate major depressive disorder blood association study meta-analysis Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Inoshita M Umehara H Watanabe S Nakataki M Kinoshita M Tomioka Y Tajima A Numata S Ohmori T Elevated peripheral blood glutamate levels in major depressive disorder
description	Masatoshi Inoshita,1 Hidehiro Umehara,1 Shin-ya Watanabe,1 Masahito Nakataki,1 Makoto Kinoshita,1 Yukiko Tomioka,1 Atsushi Tajima,2 Shusuke Numata,1 Tetsuro Ohmori1 1Department of Psychiatry, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan; 2Department of Bioinformatics and Genomics, Graduate School of Advanced Preventive Medical Sciences, Kanazawa University, Ishikawa, Japan Purpose: There is growing evidence that glutamatergic signaling may be involved in major depressive disorder (MDD). In regard to peripheral blood glutamate changes in MDD, inconsistent findings have been reported. The purpose of the present study was to evaluate whether blood glutamate levels differed between MDD patients and control participants. Materials and methods: We conducted a systematic review and meta-analysis of 12 association studies between blood glutamate levels and MDD in a total of 529 MDD patients and 590 controls. Subsequently, we conducted subgroup analyses and a meta-regression analysis to examine the sources of potential heterogeneity. Results: A random effects model showed that blood glutamate levels were significantly higher in MDD patients than in controls (standardized mean difference=0.54, 95% CI=0.27–0.82, p=8.5×10-5) with high heterogeneity (I2=75.0%, p<0.05). Subgroup analyses showed elevated glutamate levels in MDD patients compared with controls in plasma, but not serum studies, and in studies using high-performance liquid chromatography but not with mass spectrometry for glutamate assay. A meta-regression analysis showed no effects of age, gender, medication use, sample size, and published year on blood glutamate levels. Conclusion: Our findings suggest that altered glutamate levels may be implicated in MDD, which provides further evidence of glutamatergic dysfunction in MDD. Keywords: glutamate, major depressive disorder, blood, association study, meta-analysis
format	article
author	Inoshita M Umehara H Watanabe S Nakataki M Kinoshita M Tomioka Y Tajima A Numata S Ohmori T
author_facet	Inoshita M Umehara H Watanabe S Nakataki M Kinoshita M Tomioka Y Tajima A Numata S Ohmori T
author_sort	Inoshita M
title	Elevated peripheral blood glutamate levels in major depressive disorder
title_short	Elevated peripheral blood glutamate levels in major depressive disorder
title_full	Elevated peripheral blood glutamate levels in major depressive disorder
title_fullStr	Elevated peripheral blood glutamate levels in major depressive disorder
title_full_unstemmed	Elevated peripheral blood glutamate levels in major depressive disorder
title_sort	elevated peripheral blood glutamate levels in major depressive disorder
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/54d0d76e83924955bf880a6f6e951cdc
work_keys_str_mv	AT inoshitam elevatedperipheralbloodglutamatelevelsinmajordepressivedisorder AT umeharah elevatedperipheralbloodglutamatelevelsinmajordepressivedisorder AT watanabes elevatedperipheralbloodglutamatelevelsinmajordepressivedisorder AT nakatakim elevatedperipheralbloodglutamatelevelsinmajordepressivedisorder AT kinoshitam elevatedperipheralbloodglutamatelevelsinmajordepressivedisorder AT tomiokay elevatedperipheralbloodglutamatelevelsinmajordepressivedisorder AT tajimaa elevatedperipheralbloodglutamatelevelsinmajordepressivedisorder AT numatas elevatedperipheralbloodglutamatelevelsinmajordepressivedisorder AT ohmorit elevatedperipheralbloodglutamatelevelsinmajordepressivedisorder
_version_	1718400171698552832

Elevated peripheral blood glutamate levels in major depressive disorder

Ejemplares similares